Company Overview and News

 
The global financial crisis has inspired little meaningful reform, says WEF founder

2018-09-14 cnbc
The man behind the annual gathering of elites in the Swiss mountain retreat of Davos believes the financial crisis of 2008 has done little to inspire meaningful change in the banking industry. "Unfortunately, I have to say that we haven't learned too much," Klaus Schwab, founder of the World Economic Forum (WEF), told CNBC on Friday. Most analysts believe the global banking system is in a much safer position than it was before Lehman Brothers collapsed 10 years ago.
SCGLF SCGLY GLE

 
UPDATE 1-Carrefour digital chief Cheval to head French hypermarkets arm

2018-09-14 reuters
PARIS, Sept 14 (Reuters) - Carrefour picked its digital chief Marie Cheval to replace Alain Rabec as head of its French hypermarket stores, highlighting the growing importance of its digital and online businesses in its broader strategy to revive its fortunes.
SCGLF SCGLY GLE

 
Malaysian palm oil price snaps losing streak on technical correction

2018-09-13 thestar.com.my
The benchmark palm oil contract for November delivery on the Bursa Malaysia Derivatives Exchange was 0.3 percent higher at 2,243 ringgit ($541.40) a tonne at the close of trade, after hitting a two-week low in the previous session. Trading volumes stood at 27,168 lots of 25 tonnes each at the end of the trading day.
SCGLF SCGLY GLE

 
UPDATE 4-Turkish central bank raises rates sharply, boosts lira

2018-09-13 reuters
ISTANBUL (Reuters) - Turkey’s central bank raised its benchmark rate by a hefty 625 basis points on Thursday, the biggest such increase in President Tayyip Erdogan’s 15-year rule, boosting the lira and possibly easing investor concern over his influence on monetary policy.
SCGLF ACA SCGLY GLE CRARY CRARF

 
Asia Inc. Q2 profits grow at slowest pace in nearly 2 years

2018-09-13 bworldonline
ASIAN companies posted their lowest profit growth in nearly two years in the June quarter and earnings are likely to come under further pressure, weighed down by the escalating US-China trade war and high currency volatility, Reuters analyses showed.
SCGLF SCGLY GLE

 
Asia Inc second-quarter profits grow at slowest pace in nearly 2 years as trade tensions rise

2018-09-13 reuters
(Reuters) - Asian companies posted their lowest profit growth in nearly two years in the June quarter and earnings are likely to come under further pressure, weighed down by the escalating U.S.-China trade war and high currency volatility, Reuters analyses showed.
SCGLF SCGLY GLE

 
Asia Inc second-quarter profits grow at slowest pace in nearly 2 years as trade tensions rise

2018-09-13 channelnewsasia
Asian companies posted their lowest profit growth in nearly two years in the June quarter and earnings are likely to come under further pressure, weighed down by the escalating U.S.-China trade war and high currency volatility, Reuters analyses showed.
SCGLF SCGLY GLE

24
Saudi Arabia wealth fund prepares to sign US$11bil loan

2018-09-12 thestar.com.my
DUBAI: Saudi Arabia’s sovereign wealth fund will sign an US$11bil loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

 
Emerging value in Asia’s stocks not enough to win investors

2018-09-12 bworldonline
HONG KONG — Asian stocks are trading at a two-year low versus the rest of the world, but most of the region’s emerging markets are still failing to attract investors.
PSKXF SCGLF PHSXY SCGLY PSE GLE

24
Saudi wealth fund said to prepare to sign US$11 bil loan

2018-09-12 theedgemarkets
(Sept 12): Saudi Arabia’s sovereign wealth fund will sign an US$11 billion loan this week, marking its first-ever borrowing, according to people familiar with the matter.
BGX BNPQY BGLF HSB GLSSP SCGLF STAN SCBFF MS JBK TFG SCGLY BX HCS BGB BNPZY CGBBW 2888 GLE 9984 STAN SFTBF CBQS GS STAB STAC ACA HSBC SFTBY HBCYF C GSC 55BC BNPQF CRARF GSJ 0005 580001 HSEA HSEB CRARY GJS

 
Stocks inch off three-week lows but little respite for emerging markets

2018-09-12 malaymail
LONDON, Sept 12 — Fresh sparring between Washington and Beijing over trade kept world stocks close to three-week lows today, while a slight dollar pullback gave little respite to emerging markets, with the Indian rupee plumbing new record lows.
SCGLF SCGLY GLE

 
Stocks inch off 3-week lows but little respite for emerging markets

2018-09-12 thehindubusinessline
L Fresh sparring between Washington and Beijing over trade kept world stocks close to three-week lows on Wednesday, while a slight dollar pullback gave little respite to emerging markets, with the Indian rupee plumbing new record lows.
SCGLF SCGLY GLE

1
Gold falls on technical resistance, US-China trade war fears

2018-09-12 thehindubusinessline
Spot gold was down 0.3 per cent at $1,194.08 an ounce at 0406 GMT, after hitting its lowest since August 24 at $1,187.21 on Tuesday.
SCGLF SCGLY GLE 2840 GLD

 
S. Korea jobless at highest since global financial crisis, adds to president's woes

2018-09-12 malaymail
SEOUL, Sept 12 — South Korea's unemployment rate hit an eight-year high in August as mandatory minimum wages rose, adding to economic policy frustrations and political challenges for President Moon Jae-in whose approval rating is now at its lowest since inauguration.
SCGLF SCGLY GLE

26
Going against a global trend, Japan lags on boardroom diversity: study

2018-09-12 japantimes.co.jp
BANGKOK/SINGAPORE – The “old boys club” in the boardroom is alive and well — and most prevalent among the biggest Japanese and Chinese companies.
BCS BNPQY PPRUY SFTBF 83SF SCGLF 83SK PPRUF GM SFTBY 47MC FP STT SCGLY BNPQF BNPZY BABA KER 0700 GLE 9984

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EPA:GLE / SOCIETE GENERALE on message board site Silicon Investor.

Alphabet Inc. (Google) Alphabet Inc. (Google) Alphabet Inc. (Google) CFZ E-Wiggle Workspace CFZ E-Wiggle Workspace CFZ E-Wiggle Workspace
Golden Triangle Golden Triangle Golden Triangle Google Earth Google Earth Google Earth
GTI.C - Glenbriar Technologies GTI.C - Glenbriar Technologies GTI.C - Glenbriar Technologies Su0026P 500 severely overvalued? Look from five different angles Su0026P 500 severely overvalued? Look from five different angles Su0026P 500 severely overvalued? Look from five different angles
Rambus (RMBS) - Eagle or Penguin Rambus (RMBS) - Eagle or Penguin Rambus (RMBS) - Eagle or Penguin Golden Eagle Int. (MYNG) Golden Eagle Int. (MYNG) Golden Eagle Int. (MYNG)
Google Facts Zone Google Facts Zone Google Facts Zone Google - Moderated - Information and discussion Thread Google - Moderated - Information and discussion Thread Google - Moderated - Information and discussion Thread